In the pursuit to combat aging, a breakthrough was achieved as the US Food and Drug Administration (FDA) approved human clinical trials for a therapy aimed at reversing the biological age of living cells. This marked a significant milestone in medical history, transitioning the age-old quest into reality.
Life Biosciences, the company spearheading this innovation, was co-founded by renowned longevity scientist and Harvard professor, David Sinclair. Sinclair has long contended that aging is not an inevitable natural process but rather a correctable biological dysfunction. Shortly after the groundbreaking FDA clearance, Sinclair revealed at the World Governments Summit in Dubai that his team had successfully reversed the biological age of cells, organs, and complex tissues – such as the eye and brain – by up to 75% in a matter of weeks. Their experimental therapy, known as ER-100, functions by reactivating three of the four Yamanaka factors, Nobel Prize-winning proteins that rejuvenate adult cells without altering the genetic code.
The rapid advancement in this field has been greatly accelerated by artificial intelligence (AI). AI platforms have revolutionized the study of the human epigenome, the complex biochemical layer dictating gene activity above our DNA. In a landmark AI evaluation in December 2025, it was discovered that microbiome engineering plays a crucial role in clearing senescent cells, a connection human researchers had overlooked for decades. This breakthrough prompted immunologist Derya Unutmaz to revise his prediction for achieving full aging reversal from 2045 to 2040.
The economic implications of extending human lifespans are profound and are reshaping healthcare strategies globally. Research published in Nature Aging, co-authored by Sinclair and economists from prestigious institutions, estimated that extending healthy human lifespans by just one year could generate $38 trillion in economic value through increased productivity and reduced healthcare expenses. Extending healthy life by a decade could yield an astonishing $367 trillion. With a significant demographic shift expected by 2030, governments worldwide are facing challenges in sustaining pension systems and addressing healthcare demands.
Nevertheless, a pivotal question looms over the anti-aging market – the accessibility of these advancements. The current pricing models for gene therapy suggest that upcoming epigenetic treatments may be luxury commodities beyond the reach of many. This poses a critical challenge for countries like Bangladesh, where eye conditions such as cataracts, glaucoma, and diabetic retinopathy are prevalent. Bangladesh must leverage its existing research infrastructure and embrace cutting-edge technologies like AI to address the healthcare needs of its population.
As we stand on the brink of a transformative era in healthcare, societies must prepare for the implications of extended human lifespans. Adjustments to retirement ages, inheritance laws, and pension schemes will be necessary in a world where individuals in their seventies possess the biological characteristics of much younger individuals. It is imperative for global leaders and institutions to engage in proactive dialogue to shape a future where advancements in science are harnessed for the collective benefit of society.
